Canada Markets open in 15 mins
  • S&P/TSX

    21,162.65
    +400.65 (+1.93%)
     
  • S&P 500

    4,686.75
    +95.08 (+2.07%)
     
  • DOW

    35,719.43
    +492.43 (+1.40%)
     
  • CAD/USD

    0.7921
    +0.0012 (+0.1537%)
     
  • CRUDE OIL

    71.81
    -0.24 (-0.33%)
     
  • BTC-CAD

    62,143.27
    -2,655.87 (-4.10%)
     
  • CMC Crypto 200

    1,284.61
    -157.15 (-10.90%)
     
  • GOLD FUTURES

    1,781.20
    -3.50 (-0.20%)
     
  • RUSSELL 2000

    2,253.79
    +47.46 (+2.15%)
     
  • 10-Yr Bond

    1.4970
    +0.0170 (+1.15%)
     
  • NASDAQ futures

    16,327.00
    +9.00 (+0.06%)
     
  • VOLATILITY

    21.80
    -6.15 (-22.00%)
     
  • FTSE

    7,353.58
    +13.68 (+0.19%)
     
  • NIKKEI 225

    28,860.62
    +405.02 (+1.42%)
     
  • CAD/EUR

    0.7001
    -0.0013 (-0.19%)
     

Aurinia Pharmaceuticals to Release Third Quarter 2021 Financial Results on November 3, 2021

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

VICTORIA, British Columbia, October 27, 2021--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the "Company") today announced that it will release its third quarter 2021 financial results on Wednesday, November 3, 2021, before the markets open. Aurinia’s management team will also host a conference call at 8:30 a.m. ET to discuss the Company’s financial results and provide general operational and business updates.

The conference call and webcast is scheduled for November 3, 2021 8:30 a.m. ET. To participate in the conference call, please dial +1-877-407-9170 (Toll-free U.S. & Canada). An audio webcast can be accessed under "News/Events" through the "Investors" section of the Aurinia corporate website at www.auriniapharma.com. A replay of the webcast will be available on Aurinia’s website.

ABOUT AURINIA

Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The Company has introduced LUPKYNIS™ (voclosporin), the first FDA-approved oral therapy indicated for the treatment of adult patients with active lupus nephritis (LN). The Company’s head office is in Victoria, British Columbia, its U.S. commercial hub is in Rockville, Maryland, and the Company focuses its development efforts globally.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211027005062/en/

Contacts

Dana Lynch, Corporate Communications & IR
IR@auriniapharma.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting